← 返回

原位内镜光动力疗法联合未成熟 DC 疫苗接种可诱导针对腹膜癌病的强效 T 细胞应答

英文原题:In situ endoscopic photodynamic therapy combined with immature DC vaccination induces a robust T cell response against peritoneal carcinomatosis.

查看英文原题

In situ endoscopic photodynamic therapy combined with immature DC vaccination induces a robust T cell response against peritoneal carcinomatosis.

PubMed 2024/11/05(内容时间) J Immunother Cancer Q1 · IF 11.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

内窥镜光局部递送的 in situ PDT 与 iDC 给药的联合诱导了针对腹膜癌病的持久记忆免疫应答,从而为这种危及生命的病症的治疗开辟了新前景。

研究思路结论见上方概要

免疫原性细胞死亡(ICD)和铁死亡近年来已成为抗癌免疫反应中的关键因素。在能够诱导ICD及相关危险信号释放的治疗方法中,光动力疗法(PDT)是其中之一。铁死亡则源于脂质过氧化,由CD8+ T细胞在产生IFN-γ时诱导,以杀死附近的癌细胞。我们旨在将这两个概念结合起来,即评估PDT的强促氧化效应是否能促进铁死亡和抗原释放,并开发一种原位PDT操作流程,为高内吞活性的未成熟树突状细胞(iDC)过继转移准备土壤。该方法被用于管理腹膜癌病,这是一种常与不良预后相关的病变。

我们使用了由癌细胞制成的三维(3D)异型球体,将其暴露于白光激活的OR141光敏剂(PS)中,随后通过添加iDC和初始淋巴细胞使其复合化。接下来,我们使用了小鼠腹膜癌病模型,并通过腹腔镜给予PDT,利用内窥镜光局部诱导光激活。采用从原位疫苗接种小鼠中分离的免疫细胞,在体内和体外追踪了过继转移iDC后的免疫反应。

接受PDT诱导细胞死亡的癌细胞显著增加了ICD标志物和球体中iDCs的浸润,且依赖于铁死亡。这些作用诱导了CD8+和CD4+T细胞的序贯激活,表现为球体3D结构的显著破坏,并且值得注意的是,传统铁死亡诱导剂RSL3未能重现这些效应。使用内窥镜的LED光对PS进行原位光激活,使我们能够将疫苗模式应用于腹膜肿瘤小鼠。连续腹腔注射iDCs导致肿瘤生长延迟、生存率提高,并防止再挑战时的肿瘤复发。CD8+T细胞反应得到了耗竭实验、早期活化T细胞的淋巴结检测以及离体T细胞对球体诱导的细胞毒性的支持。

展开英文摘要原文

Immunogenic cell death (ICD) and ferroptosis have recently emerged as key factors in the anticancer immune response. Among the treatments able to induce ICD and the associated release of danger signals is photodynamic therapy (PDT). Ferroptosis for its part results from lipid peroxidation and is induced by CD8 + T cells to kill nearby cancer cells on IFN-γ production. We aimed to combine the two concepts, that is, to evaluate whether the strong pro-oxidant effects of PDT may promote ferroptosis and antigen release and to develop a procedure for in situ PDT to prepare the soil for highly endocytotic immature dendritic cell (iDC) adoptive transfer. This approach was implemented for managing peritoneal carcinomatosis, a lesion often associated with poor outcomes.

We used three-dimensional (3D) heterotypic spheroids made of cancer cells, exposed them to a white light-activated OR141 photosensitizer (PS), and subsequently complexified them by adding iDC and naive lymphocytes. We next used a model of mouse peritoneal carcinomatosis and administered PDT using laparoscopy to locally induce photoactivation using the endoscope light. The immune response following adoptive transfer of iDC was tracked both in vivo and ex vivo using isolated immune cells from in situ vaccinated mice.

Cancer cells undergoing PDT-induced cell death significantly increased ICD markers and the infiltration of iDCs in spheroids, relying on ferroptosis. These actions induced the sequential activation of CD8 + and CD4 + T cells as revealed by a significant spheroid 3D structure deterioration and, remarkably, were not recapitulated by conventional ferroptosis inducer RSL3. Using LED light from an endoscope for in situ photoactivation of PS enabled us to apply the vaccination modality in mice with peritoneal tumors. Consecutive intraperitoneal injection of iDCs resulted in delayed tumor growth, increased survival rates, and prevented tumor relapse on rechallenge. CD8 + T cell response was supported by depletion experiments, nodal detection of early activated T cells, and ex vivo T cell-induced cytotoxicity toward spheroids.

The combination of in situ PDT locally delivered by an endoscope light and iDC administration induces a durable memory immune response against peritoneal carcinomatosis thereby opening new perspectives for the treatment of a life-threatening condition.

论文信息

作者
Degavre C、Lepez A、Ibanez S、François C、Głowacka K、Guilbaud C、Laloux-Morris F、Esfahani H
第一作者单位
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Cancer Translational Research laboratory, UCLouvain, Brussels, Belgium.Belgium
通讯作者单位
Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Cancer Translational Research laboratory, UCLouvain, Brussels, Belgium olivier.feron@uclouvain.be.Belgium
期刊
Journal for immunotherapy of cancer2024 Nov 5
原文标识
PubMed 39500528 · DOI 10.1136/jitc-2024-009752